Summary

Question 1

Patients with neuromuscular disease have weak inspiratory, bulbar, and expiratory muscles, leading to what complications?

Answer 1

• Weak cough
• Inability to clear secretions
• Pneumonia
• Atelectasis
• Respiratory failure
• Early mortality

These complications arise due to the muscle weakness associated with neuromuscular diseases.

Question 2

What is the key clinical measure for assessing cough effectiveness in patients with neuromuscular disease?

Answer 2

Peak Cough Flow

This measure helps determine the need for assisted airway clearance.

Question 3

If Peak Cough Flow is less than 270 L/min, what action should be taken?

Answer 3

Begin assisted airway clearance

This is crucial for patients with reduced cough effectiveness.

Question 4

If Peak Cough Flow is less than 160 L/min, what does this indicate?

Answer 4

Cough is ineffective: active therapy (MAC, MI-E) required

This indicates a need for more intensive airway clearance interventions.

Question 5

What are the components of the best treatment strategy for patients with neuromuscular disease?

Answer 5

• Increase inspiratory volume
• Combine with manually assisted cough
• Use MI-E when natural cough cannot reach effective flow rates

These strategies aim to enhance respiratory function and clearance of secretions.

Question 6

What are the benefits of early and regular intervention in patients with neuromuscular disease?

Answer 6

• Improves survival
• Reduces hospitalisation
• Maintains lung/chest wall compliance
• Prevents respiratory failure

Early intervention is critical for managing complications associated with neuromuscular diseases.